The association of clinical outcome and peripheral T-cell subsets in metastatic colorectal cancer patients receiving first-line FOLFIRI plus bevacizumab therapy

OncoImmunology

Volumn 5, Issue 7, 2016, Pages

  Roselli, Mario ^a   Formica, Vincenzo ^a   Cereda, Vittore ^a   Jochems, Caroline ^b   Richards, Jacob ^b   Grenga, Italia ^b   Orlandi, Augusto ^a   Ferroni, Patrizia ^c   Guadagni, Fiorella ^c,d   Schlom, Jeffrey ^b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b NATIONAL CANCER INSTITUTE   (United States)

^c San Raffaele Roma Open University   (Italy)

^d IRCCS SAN RAFFAELE PISANA   (Italy)

Author keywords

Chemotherapy; colorectal cancer; FOLFIRI; immunotherapy; peripheral T cells; Tregs

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN;

ADULT; AGED; ARTICLE; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; DISEASE COURSE; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; MALE; METASTATIC COLORECTAL CANCER; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PERIPHERAL BLOOD MONONUCLEAR CELL; PROGRESSION FREE SURVIVAL; REGULATORY T LYMPHOCYTE; TREATMENT OUTCOME; TUMOR BIOPSY; VERY ELDERLY;

EID: 84978522783     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2016.1188243     Document Type: Article

References (25)

1. M.Camus, M.Tosolini, B.Mlecnik, F.Pages, A.Kirilovsky, A.Berger, A.Costes, G.Bindea, P.Charoentong, P.Bruneval et al. Coordination of intratumoral immune reaction and human colorectal cancer recurrence. Cancer Res 2009; 69:2685-93; PMID:19258510; http://dx.doi.org/10.1158/0008-5472.CAN-08-2654
2. J.Galon, A.Costes, F.Sanchez-Cabo, A.Kirilovsky, B.Mlecnik, C.Lagorce-Pages, M.Tosolini, M.Camus, A.Berger, P.Wind et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313:1960-4; PMID:17008531; http://dx.doi.org/10.1126/science.1129139
3. F.Pages, A.Berger, M.Camus, F.Sanchez-Cabo, A.Costes, R.Molidor, B.Mlecnik, A.Kirilovsky, M.Nilsson, D.Damotte et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005; 353:2654-66; PMID:16371631; http://dx.doi.org/10.1056/NEJMoa051424
4. F.Pages, A.Kirilovsky, B.Mlecnik, M.Asslaber, M.Tosolini, G.Bindea, C.Lagorce, P.Wind, F.Marliot, P.Bruneval et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol 2009; 27:5944-51; PMID:19858404; http://dx.doi.org/10.1200/JCO.2008.19.6147
5. C.S.Roxburgh, J.M.Salmond, P.G.Horgan, K.A.Oien, D.C.McMillan. Tumour inflammatory infiltrate predicts survival following curative resection for node-negative colorectal cancer. Eur J Cancer 2009; 45:2138-45; PMID:19409772; http://dx.doi.org/10.1016/j.ejca.2009.04.011
6. C.S.Roxburgh, J.M.Salmond, P.G.Horgan, K.A.Oien, D.C.McMillan. Comparison of the prognostic value of inflammation-based pathologic and biochemical criteria in patients undergoing potentially curative resection for colorectal cancer. Ann Surg 2009; 249:788-93; PMID:19387324; http://dx.doi.org/10.1097/SLA.0b013e3181a3e738
7. N.Turner, H.L.Wong, A.Templeton, S.Tripathy, T.Whiti Rogers, M.Croxford, I.Jones, M.Sinnathamby, J.Desai, J.Tie et al. Analysis of local chronic inflammatory cell infiltrate combined with systemic inflammation improves prognostication in stage II colon cancer independent of standard clinicopathologic criteria. Int J Cancer 2016; 138:671-8; PMID:26270488; http://dx.doi.org/10.1002/ijc.29805
8. C.R.Boland, S.N.Thibodeau, S.R.Hamilton, D.Sidransky, J.R.Eshleman, R.W.Burt, S.J.Meltzer, M.A.Rodriguez-Bigas, R.Fodde, G.N.Ranzani et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition:development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998; 58:5248-57; PMID:9823339
9. E.Y.Chang, P.B.Dorsey, J.Frankhouse, R.G.Lee, D.Walts, W.Johnson, G.Anadiotis, N.Johnson. Combination of microsatellite instability and lymphocytic infiltrate as a prognostic indicator in colon cancer. Arch Surg 2009; 144:511-5; PMID:19528382; http://dx.doi.org/10.1001/archsurg.2009.40
10. H.K.Lyerly, A.Hobeika, D.Niedzwiecki, T.Osada, J.Marshall, C.R.Garrett, D.Z.Chang, M.Aklilu, T.S.Crocenzi, D.J.Cole et al. A dendritic cell-based vaccine effects on T-cell responses compared with a viral vector vaccine when administered to patients following resection of colorectal metastases in a randomized phase II study. 2011 ASCO Annual Meeting. J Clin Oncol 2011; 29(suppl):abstr 2533
11. M.Morse, D.Niedzwiecki, J.Marshall, C.R.Garrett, D.Z.Chang, M.Aklilu, T.S.Crocenzi, D.J.Cole, S.Dessureault, A.Hobeika et al. Survival rates among patients vaccinated following resection of colorectal cancer metastases in a phase II randomized study compared with contemporary controls. 2011 ASCO Annual Meeting. J Clin Oncol 2011; 29(suppl):abstr 3557
12. J.P.Balint, E.S.Gabitzsch, A.Rice, Y.Latchman, Y.Xu, G.L.Messerschmidt, A.Chaudhry, M.A.Morse, F.R.Jones. Extended evaluation of a phase 1/2 trial on dosing, safety, immunogenicity, and overall survival after immunizations with an advanced-generation Ad5 [E1-, E2b-]-CEA(6D) vaccine in late-stage colorectal cancer. Cancer Immunol Immunother 2015; 64:977-87; PMID:25956394; http://dx.doi.org/10.1007/s00262-015-1706-4
13. R.Harrop, N.Connolly, I.Redchenko, J.Valle, M.Saunders, M.G.Ryan, K.A.Myers, N.Drury, S.M.Kingsman, R.E.Hawkins et al. Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control:a phase I/II trial. Clin Cancer Res 2006; 12:3416-24; PMID:16740766; http://dx.doi.org/10.1158/1078-0432.CCR-05-2732
14. M.von Mehren, P.Arlen, J.Gulley, A.Rogatko, H.S.Cooper, N.J.Meropol, R.K.Alpaugh, M.Davey, S.McLaughlin, M.T.Beard et al. The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma. Clin Cancer Res 2001; 7:1181-91; PMID:11350882
15. O.Adotevi, H.Pere, P.Ravel, N.Haicheur, C.Badoual, N.Merillon, J.Medioni, S.Peyrard, S.Roncelin, V.Verkarre et al. A decrease of regulatory T cells correlates with overall survival after sunitinib-based antiangiogenic therapy in metastatic renal cancer patients. J Immunother 2010; 33:991-8; PMID:20948437; http://dx.doi.org/10.1097/CJI.0b013e3181f4c208
16. J.H.Finke, B.Rini, J.Ireland, P.Rayman, A.Richmond, A.Golshayan, L.Wood, P.Elson, J.Garcia, R.Dreicer et al. Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res 2008; 14:6674-82; PMID:18927310; http://dx.doi.org/10.1158/1078-0432.CCR-07-5212
17. J.S.Ko, P.Rayman, J.Ireland, S.Swaidani, G.Li, K.D.Bunting, B.Rini, J.H.Finke, P.A.Cohen. Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. Cancer Res 2010; 70:3526-36; PMID:20406969; http://dx.doi.org/10.1158/0008-5472.CAN-09-3278
18. J.S.Ko, A.H.Zea, B.I.Rini, J.L.Ireland, P.Elson, P.Cohen, A.Golshayan, P.A.Rayman, L.Wood, J.Garcia et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 2009; 15:2148-57; PMID:19276286; http://dx.doi.org/10.1158/1078-0432.CCR-08-1332
19. M.Roselli, V.Cereda, M.G.di Bari, V.Formica, A.Spila, C.Jochems, B.Farsaci, R.Donahue, J.L.Gulley, J.Schlom et al. Effects of conventional therapeutic interventions on the number and function of regulatory T cells. Oncoimmunology 2013; 2:e27025; PMID:24353914; http://dx.doi.org/10.4161/onci.27025
20. B.Farsaci, J.P.Higgins, J.W.Hodge. Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy. Int J Cancer 2012; 130:1948-59; PMID:21633954; http://dx.doi.org/10.1002/ijc.26219
21. S.R.Gameiro, J.A.Caballero, J.P.Higgins, D.Apelian, J.W.Hodge. Exploitation of differential homeostatic proliferation of T-cell subsets following chemotherapy to enhance the efficacy of vaccine-mediated antitumor responses. Cancer Immunol Immunother 2011; 60:1227-42; PMID:21544650; http://dx.doi.org/10.1007/s00262-011-1020-8
22. M.Vergati, V.Cereda, R.A.Madan, J.L.Gulley, N.Y.Huen, C.J.Rogers, K.W.Hance, P.M.Arlen, J.Schlom, K.Y.Tsang. Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- vs. post-vaccination. Cancer Immunol Immunother 2011; 60:197-206; PMID:20976449; http://dx.doi.org/10.1007/s00262-010-0927-9
23. A.Ferlosio, G.Arcuri, E.Doldo, M.G.Scioli, S.De Falco, L.G.Spagnoli, A.Orlandi. Age-related increase of stem marker expression influences vascular smooth muscle cell properties. Atherosclerosis 2012; 224:51-7; PMID:22857896; http://dx.doi.org/10.1016/j.atherosclerosis.2012.07.016
24. M.M.Bertagnolli, D.Niedzwiecki, C.C.Compton, H.P.Hahn, M.Hall, B.Damas, S.D.Jewell, R.J.Mayer, R.M.Goldberg, L.B.Saltz et al. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer:Cancer and Leukemia Group B Protocol 89803. J Clin Oncol 2009; 27:1814-21; PMID:19273709; http://dx.doi.org/10.1200/JCO.2008.18.2071
25. J.Garcia-Solano, P.Conesa-Zamora, P.Carbonell, J.Trujillo-Santos, D.D.Torres-Moreno, I.Pagan-Gomez, E.Rodriguez-Braun, M.Perez-Guillermo. Colorectal serrated adenocarcinoma shows a different profile of oncogene mutations, MSI status and DNA repair protein expression compared to conventional and sporadic MSI-H carcinomas. Int J Cancer 2012; 131:1790-9; PMID:22287190; http://dx.doi.org/10.1002/ijc.27454